Clinical trials: Psoriasis Patients
Psoriasis
Efficacy of Alitretinoin Treatment in Patients With Pustular Form of Psoriasis
The main purpose of this study is to demonstrate the improvement in the skin condition rate of patients receiving alitretinoin compared to patients receiving placebo.
- Trial name
- NCT01245140
- Testing
- alitretinoin
- Where
- 8 sites in France, Germany and 2 more
- Volunteers
- 33 people
- Sponsor
- Stiefel, a GSK Company
Psoriasis
Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques
The purpose of this study is to determine the safety, metabolism and potential effect of drug product SFA-002 on mild moderate and severe chronic plaque psoriasis.
- Trial name
- NCT05642182
- Testing
- SFA002
- Where
- 3 sites in United States
- Volunteers
- 90 people
- Sponsor
- SFA Therapeutics
Plaque Psoriasis
Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis
Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin.
- Trial name
- DREAM (NCT07039110)
- Where
- 84 sites in Canada, Czechia and 6 more
- Volunteers
- 700 people
- Sponsor
- AbbVie
Plaque Psoriasis
Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy
The purpose of this study is to assess the efficacy, safety and tolerability of Tildrakizumab in moderate-to-severe plaque psoriasis participants who are non-responder to Dimethyl fumarate (DMF) at Week 16.
- Trial name
- TRANSITION (NCT04263610)
- Testing
- Dimethyl fumarate (DMF) standard scheme, Dimethyl fumarate (DMF) simplified scheme, Tildrakizumab
- Where
- 3 sites in Germany, United Kingdom
- Volunteers
- 190 people
- Sponsor
- Almirall, S.A.
Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of Subcutaneous DMB-3115 Versus Stelara® in Patients With Moderate to Severe Chronic Plaque Psoriasis
This study is designed to evaluate efficacy, safety, pharmacokinetics (PK) and immunogenicity of subcutaneously administered DMB-3115 in comparison with Stelara for treatment of moderate to severe chronic plaque psoriasis.
- Trial name
- Opportuniti (NCT04785326)
- Testing
- DMB-3115, Stelara
- Where
- 2 sites in United States
- Volunteers
- 598 people
- Sponsor
- Dong-A ST Co., Ltd.
Psoriasis Vulgaris
A Study Comparing LEO 80190 Ointment With Hydrocortisone Ointment, Both Applied Once Daily in the Treatment of Psoriasis Vulgaris on the Face and Intertriginous Areas
An international, multi-centre, prospective, randomised, double-blind, active-controlled, 2-arm, parallel group, 8-week, phase 3 clinical study in paediatric patients (aged 6 to 17 years) with psoriasis vulgaris on the face and…
- Trial name
- NCT01007591
- Testing
- LEO 80190, Hydrocortisone
- Where
- France
- Volunteers
- 40 people
- Sponsor
- LEO Pharma
Psoriasis Vulgaris
Phase I Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris
The purpose of this clinical research study is to determine the safety, pharmacokinetics, immunogenicity in humans, the recovery time required from the biologic effects and the optimal biologic dose range of BMS188667 (CTLA4Ig)
- Trial name
- NCT00306878
- Testing
- Abatacept
- Where
- 5 sites in United States
- Volunteers
- 45 people
- Sponsor
- Bristol-Myers Squibb
Psoriasis
Study to Evaluate the Efficacy of Infliximab Induction Therapy for Patients With Palmoplantar Psoriasis (PPP)(Study P04555)(COMPLETED)
Subjects with psoriasis will receive intravenous infliximab 5 mg/kg given over a 2-hour period at Weeks 0, 2, and 6 (induction therapy) to evaluate the efficacy of infliximab at Week 18.
- Trial name
- TIPS (NCT00686686)
- Testing
- Infliximab
- Volunteers
- 23 people
- Sponsor
- Merck Sharp & Dohme LLC
Psoriasis
Post-Marketing Surveillance Study of Adalimumab in Pediatric Chronic Severe Plaque Psoriasis Patients in Korea
The objective of this study is to evaluate the real world safety and effectiveness of adalimumab (Humira) for the treatment of Korean patients with pediatric chronic severe plaque psoriasis under a routine treatment practice.
- Trial name
- ped PsO rPMS (NCT03925441)
- Where
- South Korea
- Volunteers
- 2 people
- Sponsor
- AbbVie
Scalp Psoriasis
Parallel Group Trial to Evaluate the Efficacy and Safety of Loion® Compared to 10% Salicylic Acid in Patients With Chronic Psoriasis Capitis
The study will be conducted to evaluate the efficacy and safety of a topical dimeticone formulation (Loion®) compared to 10% salicylic acid in octyl-dodecanol with 15% Macrogol-4-laurylether for the removal of scaling in patients…
- Trial name
- NCT01914627
- Testing
- Dimethicone, Salicylic Acid
- Where
- Germany
- Volunteers
- 90 people
- Sponsor
- G. Pohl-Boskamp GmbH & Co. KG
Palmoplantar Pustulosis (PPP)
A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar Pustulosis
The primary objective is to provide dose-ranging data for 4 dose regimens of BI 655130 compared to placebo on the primary endpoint of percentage change from baseline in PPP ASI at Week 16.
- Trial name
- NCT04015518
- Testing
- Spesolimab
- Where
- 88 sites in United States, Australia and 13 more
- Volunteers
- 152 people
- Sponsor
- Boehringer Ingelheim
Psoriasis
A Study to Assess the Effect of Ustekinumab (Stelara®) and Etanercept (Enbrel®) in Participants With Moderate to Severe Psoriasis (MK-0000-206)
This is a two-part study. The purpose of the pilot study (Part 1) is to optimize the acquisition, handling and shipping procedure for skin biopsies obtained from participants with plaque psoriasis.
- Trial name
- NCT01276847
- Testing
- Ustekinumab, Etanercept
- Volunteers
- 40 people
- Sponsor
- Merck Sharp & Dohme LLC
Psoriasis
A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis With Involvement of the Scalp
This was a Phase IV randomized, double-blind, placebo-controlled study designed to evaluate the safety and efficacy of subcutaneous efalizumab in adult patients (18 years of age and older) with chronic moderate to severe plaque…
- Trial name
- SCALP (NCT00669214)
- Testing
- efalizumab
- Volunteers
- 89 people
- Sponsor
- Genentech, Inc.
Psoriasis
HPP737 in Adult Patients With Moderate-to-severe Plaque Psoriasis.
The goal of this clinical trial is to learn if drug HPP737 works to treat moderate-to-severe plaque psoriasis in adults. It will also learn about the safety of drug HPP737.
- Trial name
- NCT07712705
- Testing
- HPP737
- Where
- 50 sites in China
- Volunteers
- 515 people
- Sponsor
- Newsoara Biopharma Co., Ltd.
Psoriasis
A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2)
This study will assess the safety and efficacy of ixekizumab (LY2439821) compared to etanercept and placebo in participants with moderate to severe chronic plaque psoriasis.
- Trial name
- UNCOVER-2 (NCT01597245)
- Testing
- 80 mg ixekizumab Dosing Regimen, 50 mg etanercept
- Where
- 118 sites in United States, Australia and 10 more
- Volunteers
- 1,224 people
- Sponsor
- Eli Lilly and Company
Plaque Psoriasis
Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis.
- Trial name
- EVERLAST-B (NCT07290569)
- Testing
- ORKA-001
- Where
- 36 sites in United States, Canada and 2 more
- Volunteers
- 160 people
- Sponsor
- Oruka Therapeutics, Inc.
Generalized Pustular Psoriasis
A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis
This is a study in adolescents and adults with Generalized Pustular Psoriasis (GPP). People between 12 and 75 years old can take part in the study.
- Trial name
- NCT04399837
- Testing
- Spesolimab
- Where
- 72 sites in United States, Argentina and 21 more
- Volunteers
- 123 people
- Sponsor
- Boehringer Ingelheim
Psoriasis
Double-blind, Randomised, Placebo-controlled Trial Investigating BIRT 2584 XX in Patients With Moderate/Severe Psoriasis
The purpose of this clinical study is to determine the effectiveness, pharmacokinetics and safety of several doses of BIRT 2584 XX (100mg, 300mg and 500mg) taken once daily in the treatment of moderate to severe plaque-type…
- Trial name
- NCT00333411
- Testing
- BIRT 2584 XX
- Where
- 48 sites in Belgium, Canada and 8 more
- Volunteers
- 360 people
- Sponsor
- Boehringer Ingelheim
Psoriasis
Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis
This is a multicenter, randomized, double-blind, placebo-controlled, phase III clinical study which is designed to determine the efficacy, safety, immunogenicity and pharmacokinetics, and pharmacodynamics of HB0017 Injection in…
- Trial name
- NCT06477237
- Testing
- HB0017 Q4W, HB0017 Q8W
- Where
- 44 sites in China
- Volunteers
- 408 people
- Sponsor
- Huabo Biopharm Co., Ltd.
Psoriatic Arthritis
A Study to Characterize Profile of Participant With Psoriatic Arthritis Depending on Whether Their Disease is Managed by a Dermatologist or by a Rheumatologist, and Starting Ustekinumab
The primary purpose of this study is to describe the Psoriatic Arthritis (PsA) participant profiles depending on whether their disease is managed by a dermatologist or by a rheumatologist in routine practice.
- Trial name
- PROUST (NCT03336281)
- Testing
- Ustekinumab
- Where
- France
- Volunteers
- 221 people
- Sponsor
- Janssen Cilag S.A.S.